ResMed Company Insiders

RMD Stock  USD 249.56  5.78  2.37%   
ResMed's insiders are aggressively selling. The analysis of insiders' sentiment of trading ResMed Inc stock suggests that all insiders are panicking at this time. ResMed employs about 34 people. The company is managed by 34 executives with a total tenure of roughly 155 years, averaging almost 4.0 years of service per executive, having 1.0 employees per reported executive.
Michael Farrell  CEO
Chief Executive Officer, Director
Peter Farrell  Chairman
Non-Executive Chairman of the Board

ResMed's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-22Justin LeongDisposed 6160 @ 243.09View
2024-11-12Witte Jan DeDisposed 796 @ 248.81View
2024-11-06Peter C FarrellDisposed 2000 @ 248.74View
2024-11-01Michael J RiderDisposed 69 @ 242View
2024-10-11Kaushik GhoshalDisposed 4260 @ 238.48View
2024-10-08Brett SandercockDisposed 1000 @ 233.47View
2024-10-07Michael J FarrellDisposed 14683 @ 231.91View
2024-10-02Peter C FarrellDisposed 2000 @ 237.2View
2024-09-12Kaushik GhoshalDisposed 5000 @ 252.56View
2024-09-09Brett SandercockDisposed 1000 @ 246.42View
2024-09-04Peter C FarrellDisposed 2000 @ 239.9View
2024-08-20Michael J RiderDisposed 882 @ 231View
2024-08-08Brett SandercockDisposed 1000 @ 212.16View
2024-08-07Michael J FarrellDisposed 14683 @ 214.25View
2024-08-05Justin LeongDisposed 48000 @ 217.07View
2024-07-08Michael J FarrellDisposed 14683 @ 192.97View
2024-06-10Brett SandercockDisposed 1000 @ 209.81View
Monitoring ResMed's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

ResMed's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ResMed's future performance. Based on our forecasts, it is anticipated that ResMed will maintain a workforce of about 230 employees by December 2024.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

ResMed's latest congressional trading

Congressional trading in companies like ResMed Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in ResMed by those in governmental positions are based on the same information available to the general public.
2024-06-14Senator Tommy TubervilleAcquired Under $15KVerify
2024-06-13Senator Tommy TubervilleAcquired Under $15KVerify
2023-11-16Senator Tommy TubervilleAcquired Under $15KVerify
2023-11-15Senator Tommy TubervilleAcquired Under $15KVerify

ResMed Management Team Effectiveness

The company has Return on Asset of 0.1327 % which means that on every $100 spent on assets, it made $0.1327 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2357 %, implying that it generated $0.2357 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.30, whereas Return On Capital Employed is forecasted to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 482.8 M, whereas Net Tangible Assets are forecasted to decline to about 632.7 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 147.7 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 1.1 B

ResMed Workforce Comparison

ResMed Inc is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 226,296. ResMed adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.

ResMed Profit Margins

The company has Net Profit Margin of 0.23 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.32 %, which entails that for every 100 dollars of revenue, it generated $0.32 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.670.5667
Fairly Up
Pretty Stable
Net Profit Margin0.130.2179
Way Down
Very volatile
Operating Profit Margin0.160.2817
Way Down
Slightly volatile
Pretax Profit Margin0.180.27
Way Down
Pretty Stable
Return On Assets0.0960.1486
Way Down
Pretty Stable
Return On Equity0.140.2099
Way Down
Pretty Stable

ResMed Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ResMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on ResMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ResMed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.56
14
25
 53,543 
 96,782 
2024-09-01
1.0
18
18
 114,285 
 169,894 
2024-06-01
0.2857
4
14
 41,366 
 154,265 
2023-12-01
0.6071
17
28
 146,813 
 49,243 
2023-09-01
0.6429
9
14
 43,273 
 38,005 
2023-06-01
0.1579
3
19
 17,025 
 75,150 
2023-03-01
0.1765
3
17
 17,025 
 60,563 
2022-12-01
0.6889
31
45
 298,390 
 224,546 
2022-09-01
0.5
10
20
 65,592 
 101,544 
2022-06-01
0.3125
5
16
 27,525 
 82,209 
2022-03-01
0.3158
6
19
 41,025 
 105,357 
2021-12-01
0.9655
28
29
 226,504 
 219,811 
2021-09-01
0.5833
7
12
 52,464 
 93,665 
2021-06-01
0.25
2
8
 16,000 
 37,425 
2021-03-01
0.5714
4
7
 13,526 
 11,478 
2020-12-01
0.8148
22
27
 273,362 
 166,060 
2020-09-01
0.6
6
10
 39,393 
 38,819 
2020-06-01
0.3636
4
11
 22,417 
 38,207 
2020-03-01
0.3333
5
15
 27,515 
 71,763 
2019-12-01
0.6327
31
49
 480,944 
 299,504 
2019-09-01
0.48
12
25
 72,525 
 105,609 
2019-06-01
0.4571
16
35
 115,253 
 213,777 
2019-03-01
0.4583
11
24
 50,121 
 96,244 
2018-12-01
0.7143
25
35
 507,185 
 208,121 
2018-09-01
1.1667
7
6
 55,244 
 16,860 
2018-06-01
0.6154
8
13
 69,889 
 134,512 
2018-03-01
0.3636
4
11
 34,364 
 75,613 
2017-12-01
0.7381
31
42
 518,203 
 496,775 
2017-09-01
0.7222
13
18
 225,966 
 215,265 
2017-06-01
0.6316
12
19
 229,147 
 389,807 
2017-03-01
0.4706
8
17
 107,498 
 239,996 
2016-12-01
0.6364
21
33
 406,410 
 288,651 
2016-09-01
0.64
16
25
 264,512 
 407,732 
2016-06-01
0.4737
9
19
 95,925 
 211,850 
2016-03-01
0.4545
15
33
 189,539 
 412,787 
2015-12-01
0.4717
25
53
 507,728 
 336,004 
2015-09-01
0.5588
19
34
 312,252 
 401,464 
2015-06-01
0.4286
15
35
 167,924 
 409,348 
2015-03-01
0.5581
24
43
 585,365 
 769,482 
2014-12-01
0.5111
23
45
 457,305 
 711,670 
2014-09-01
0.5135
19
37
 399,116 
 276,215 
2014-06-01
0.5556
20
36
 408,829 
 520,729 
2014-03-01
0.4545
10
22
 104,114 
 460,114 
2013-12-01
0.4444
20
45
 235,879 
 436,783 
2013-09-01
0.8
16
20
 318,947 
 438,103 
2013-06-01
0.4138
12
29
 245,500 
 587,567 
2013-03-01
0.619
13
21
 782,833 
 1,150,430 
2012-12-01
0.5806
18
31
 385,856 
 357,084 
2012-09-01
0.6667
20
30
 616,138 
 996,894 
2012-06-01
0.5
9
18
 371,789 
 756,037 
2012-03-01
0.5833
7
12
 232,500 
 431,000 
2011-12-01
0.6774
21
31
 882,932 
 621,173 
2011-09-01
1.2222
11
9
 390,745 
 663,997 
2011-06-01
0.5
4
8
 163,000 
 185,000 
2011-03-01
0.5909
13
22
 271,090 
 471,680 
2010-12-01
0.6429
36
56
 1,622,480 
 1,413,131 
2010-09-01
0.8889
16
18
 298,571 
 320,000 
2010-06-01
0.4857
17
35
 213,600 
 626,383 
2010-03-01
0.3714
13
35
 196,480 
 454,360 
2009-12-01
0.4615
18
39
 500,877 
 725,763 
2009-09-01
0.3125
10
32
 114,000 
 259,500 
2009-06-01
0.3333
3
9
 20,666 
 51,332 
2009-03-01
0.3636
8
22
 96,385 
 164,691 
2008-12-01
1.5714
11
7
 618,000 
 56,000 
2008-09-01
0.5
8
16
 71,486 
 155,852 
2008-06-01
0.5385
7
13
 58,820 
 81,002 
2007-12-01
0.6875
11
16
 576,000 
 428,675 
2007-09-01
0.2857
2
7
 56,000 
 212,500 
2007-06-01
0.2857
2
7
 5,650 
 29,650 
2007-03-01
0.2973
11
37
 179,694 
 412,294 
2006-12-01
0.9474
18
19
 484,350 
 379,241 
2006-09-01
4.5
9
2
 146,000 
 64,696 
2006-06-01
0.5333
8
15
 128,850 
 239,315 
2006-03-01
0.7857
11
14
 418,180 
 274,075 
2005-12-01
0.375
6
16
 96,286 
 230,572 
2005-09-01
0.4286
9
21
 107,000 
 64,000 
2005-06-01
0.1429
3
21
 32,000 
 94,000 
2005-03-01
0.4516
14
31
 219,000 
 196,000 
2004-12-01
0.2941
10
34
 74,108 
 185,900 
2004-09-01
0.3077
12
39
 150,600 
 128,200 
2004-06-01
0.0909
3
33
 18,600 
 113,200 
2004-03-01
0.0732
3
41
 22,400 
 231,467 
2003-12-01
0.2286
8
35
 106,974 
 124,613 
2003-09-01
0.2778
15
54
 159,600 
 306,550 
2003-06-01
0.125
1
8
 15,000 
 85,700 

ResMed Notable Stakeholders

A ResMed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ResMed often face trade-offs trying to please all of them. ResMed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ResMed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
AM BEChair FounderProfile
Michael FarrellChief Executive Officer, DirectorProfile
Peter FarrellNon-Executive Chairman of the BoardProfile
Bobby GhoshalChief Technology Officer, President - SaaS businessProfile
Jim HollingsheadPresident – sleep and respiratory care businessProfile
Richard McHalePresident – Respiratory Care BusinessProfile
Robert DouglasPresident, Chief Operating OfficerProfile
Raj SodhiPresident – Software as a Service (SaaS) Business and CTOProfile
Brett SandercockCFO and Principal Accounting OfficerProfile
Urvashi TyagiChief Technology OfficerProfile
Ronald TaylorLead Independent DirectorProfile
Harjit GillIndependent DirectorProfile
Carol BurtIndependent DirectorProfile
Jan WitteIndependent DirectorProfile
Karen DrexlerIndependent DirectorProfile
Richard SulpizioIndependent DirectorProfile
Michael RiderChief SecretaryProfile
Vered KeisarChief OfficerProfile
Carlos MDChief OfficerProfile
Kaushik GhoshalChief SaaSProfile
Michael FlissChief OfficerProfile
Rajwant SodhiPresident – Software as a Service Business (SaaS)Profile
BE MBACEO DirectorProfile
AM AMFounder ChairmanProfile
Constance BienfaitDirector RelationsProfile
Hemanth ReddyChief OfficerProfile
Dawn HaakeChief OfficerProfile
Justin LeongPresident – Asia and Latin AmericaProfile
YvonneKatrin PucknatChief OfficerProfile
Amy WakehamVP CommunicationsProfile
David PendarvisChief Administrative Officer, Global General Counsel, SecretaryProfile
Jim EllisChief OfficerProfile
Alastair RobertsonChief OfficerProfile
Todd FriedmanChief OfficerProfile

About ResMed Management Performance

The success or failure of an entity such as ResMed Inc often depends on how effective the management is. ResMed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ResMed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ResMed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.29  0.30 
Return On Capital Employed 0.22  0.14 
Return On Assets 0.15  0.10 
Return On Equity 0.21  0.14 
Please note, the presentation of ResMed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ResMed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ResMed's management manipulating its earnings.

ResMed Workforce Analysis

Traditionally, organizations such as ResMed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ResMed within its industry.

ResMed Manpower Efficiency

Return on ResMed Manpower

Revenue Per Employee137.8M
Revenue Per Executive137.8M
Net Income Per Employee30M
Net Income Per Executive30M
Working Capital Per Employee42.6M
Working Capital Per Executive42.6M

Complementary Tools for ResMed Stock analysis

When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume